LRRK2 and Parkinson disease: Given that LRRK2-associated PD patients also present with clinical and neuropathological profiles largely indistinguishable from late-onset idiopathic PD, an exciting prospect is that LRRK2 kinase inhibitors may have broader applicability to the idiopathic PD population3.